Nervous Disorder TRIZ Cases

Oral 3,4-diaminopyridine phosphate salt treats sexual dysfunction by blocking potassium channels to improve neuronal excitability.

CTX0E03 neural stem cells resolve side effects from chronic drug therapy by modulating inflammation to treat depression and schizophrenia.

A peptide sequence binds human transferrin receptors to enable transport across the blood-brain barrier.

Isolates somatic stem cells from bodily fluids using divalent cation chelating agents to activate cell cycles and expand pluripotent populations.

Specific crystalline modifications of AHU377 calcium salt resolve hygroscopicity and inconsistent water content via optimized solvent parameters.

Thiophenyl derivatives bind snRNPs to alter gene product levels, avoiding complex delivery systems required by oligonucleotide therapies.

Low-dose Pediococcus pentosaceus with minerals removes harmful substances without side effects from high probiotic doses.

Combining DBH inhibitors with L-DOPS bypasses noradrenaline deficiency to restore dopamine levels and improve memory function in Alzheimer's patients.

Juniperus communis extract containing agathadiol acts as a positive allosteric modulator to enhance cannabinoid type 1 receptor signaling.

Small peptide chemokine antagonists promote synapse and dendritic spine formation to restore neuronal connectivity.

Engineered TCR fusion proteins improve tumor killing while reducing pro-inflammatory cytokine release via separated antigen recognition and signaling functions.

Pseudotyped rAAV vectors enable sustained gene expression, restoring neuromuscular junction integrity and improving respiratory function in Pompe disease.

An orally disintegrable effervescent fentanyl tablet enhances mucosal absorption through rapid gas generation.

Bifidobacterium strain AH1205 mediates host immunity by reducing pro-inflammatory cytokines and excluding pathogenic microorganisms from the gut.

Novel Streptomyces-derived compounds inhibit nitric oxide production in microglial cells to address neuroinflammatory disease mechanisms.

Vascular endothelial damaging agents disrupt biological barriers to increase therapeutic cell enrichment at target sites.

Human anti-NGF antibodies bind nerve growth factor to reduce nociceptor responses and alleviate pain.

Predictive SNPs in the CYP1A2 gene identify patient populations likely to respond to alpha 7 nicotinic acetylcholine receptor activator treatment.

Small molecule cocktails reprogram non-neuronal cells into neuron-like phenotypes without viral vectors.

Targets multiple molecular pathways simultaneously to extend survival beyond the two-month limit of existing ALS therapies.

A Chinese herbal composition replaces toxic ingredients with non-irritating alternatives to deliver analgesic and anti-inflammatory effects.

Engineered AAV5 capsid variants with specific amino acid substitutions enhance CNS tropism for targeted gene delivery.

Multispecific polypeptides bind TCR and CD123 to redirect T cells, resolving target-independent activation and infusion requirements.

A neurotensin peptide conjugated with a transport vector crosses the blood-brain barrier to deliver therapeutic agents directly to the central nervous system.

Novel bicyclic compounds selectively inhibit retroviral splicing events to treat infections without cellular toxicity.

A22K acylated insulin derivatives eliminate zinc hexamer formation to achieve faster subcutaneous absorption and prandial-like time-action profiles.

A combination of high and low molecular weight fatty acids enhances transdermal drug permeation through skin lipid bilayer disruption.

Extracting neurofilament light protein as a single biomarker simplifies vascular cognitive impairment diagnosis while Ang-(1-7) peptides reverse deficits.

A transdermal dextromethorphan patch delivers therapeutic plasma concentrations using a skin permeation enhancer and crystallization inhibitor.

Hapten-conjugated vaccine formulations induce specific immune responses to neutralize drugs and reduce relapse rates.

Administering metformin or amlexanox increases dendritic spine density, preventing age-associated cognitive decline.

A varenicline solid formulation incorporates a nitrite scavenger agent to prevent the formation of carcinogenic N-nitroso-varenicline impurities.

TfR-binding conjugates transport oligonucleotides across the blood-brain barrier, bypassing invasive intrathecal delivery and uneven distribution.

Antibodies target the deleted exon 2-7 region of EGFRvIII, sparing normal tissues that express wild-type EGFR.

Oral freeze-dried Hypericum perforatum extracts containing hypericin lower neuropathic pain thresholds without causing adverse behavioral effects.

4-thioxothiazolidinone derivatives inhibit Top1 and Tdp1 enzymes to treat cancer.

12-Imidazolyl-1-dodecanol blocks cytochrome P450 2E1 and 2J2 activity, reducing reactive oxygen species while extending chemotherapy residence time.

Modified molecular structures optimize pharmacokinetic profiles to overcome insufficient brain penetrance in existing inhibitors.

Plasma exchange with albumin replaces withdrawn fluid to remove harmful autoantibodies, addressing limited effectiveness of standard treatments.

Nicotinamide and FGF4 culture medium expands mesenchymal stem cells, preventing premature senescence and heterogeneity during prolonged proliferation.

A CN2097-like cyclic-GluR6 analog modulates PSD-95 PDZ domains to induce long-term potentiation in neuronal synapses.

Microbial transglutaminase links amino acid-based linkers to antibody glutamine residues via primary amines.

Amino acid substitutions at positions 73, 175, and 176 prevent conversion to the neurotoxic proNGF-B variant during large-scale production.

Replication-incompetent AAV vectors deliver functional XPG, CSA, or CSB proteins to restore cellular DNA repair mechanisms in Cockayne Syndrome.

Complement inhibitors reduce C3a and C5a activity to protect brain tissue from injury.

Replacing toxic acetonitrile with protic solvents eliminates hazardous waste while maintaining high yield and purity for large-scale manufacturing.

Composite micronutrients reverse advanced glycation end products, addressing oxidative stress in diabetes.